No Data
No Data
Express News | PAVmed Inc: Files for Mixed Shelf Offering of up to $125 Mln
Lucid Diagnostics Partners With VITALExam, To Enhance Access To Lucid's EsoGuard Esophageal DNA Test For Firefighters At Risk For Esophageal Precancer
Express News | Prospective Clinical Utility Study of Lucid Diagnostics' Esoguard® Esophageal DNA Test Accepted for Peer-Reviewed Publication
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard Esophageal DNA Test Accepted for Peer-Reviewed Publication
PAVmed Is Maintained at Buy by Ascendiant Capital
PAVmed Analyst Ratings